Enclomiphene Citrate Manufacturing, Supply & Shortage History

What Enclomiphene Citrate Is and How It Works

Enclomiphene citrate is the pharmacologically active trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM) that has been prescribed for ovulatory dysfunction since 1967. Standard clomiphene (brand name Clomid) is a roughly 62:38 mixture of the two geometric isomers: enclomiphene (trans) and zuclomiphene (cis) 1. The distinction matters because the two isomers behave differently at estrogen receptors and carry different half-lives.

Enclomiphene binds estrogen receptors in the hypothalamus and anterior pituitary, blocking the negative-feedback signal that estradiol normally sends to suppress gonadotropin release. With that brake removed, the pituitary increases secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH drives Leydig cells in the testes to produce testosterone, while FSH supports Sertoli cell function and spermatogenesis 2. This dual action is the reason clinicians prescribe enclomiphene for men with secondary hypogonadism who want to preserve fertility, a goal that exogenous testosterone therapy directly undermines.

Zuclomiphene, the cis-isomer, has a much longer half-life (weeks versus hours) and carries mixed agonist-antagonist estrogenic activity that can accumulate with repeated dosing. Isolating enclomiphene was intended to retain the testosterone-boosting effect while reducing estrogenic side effects like visual disturbances and mood changes associated with the racemic mixture 3.

In the Kim et al. trial published in BJU International (2016, N=48), enclomiphene citrate 25 mg daily raised mean serum testosterone from 225 ng/dL to 455 ng/dL over 12 weeks while maintaining sperm concentration above baseline 1. That result separated enclomiphene from exogenous testosterone, which typically suppresses sperm counts to azoospermic or severely oligospermic levels within 3 to 6 months.

The Androxal Story: From Phase III to Complete Response Letter

Repros Therapeutics, a small Houston-based specialty pharma company, developed enclomiphene citrate under the brand name Androxal for the treatment of secondary hypogonadism in men with low testosterone. The drug sailed through Phase II trials showing dose-dependent testosterone increases with a favorable side-effect profile 4.

Two Phase III trials, ZA-301 and ZA-302, enrolled over 600 men. Both met their co-primary endpoints: normalization of morning testosterone levels and maintenance of sperm counts. These results were submitted to the FDA in a New Drug Application in late 2014. The advisory-committee stage looked promising. Then the process stalled.

In December 2015, the FDA issued a Complete Response Letter (CRL) requesting additional clinical data, specifically a longer-term study assessing cardiovascular outcomes. The agency's concern was not unique to enclomiphene. It followed the FDA's 2015 label-change mandate for all approved testosterone products, requiring warnings about potential cardiovascular risk 5. Repros, with limited capital for a large outcomes trial, never resubmitted. The company eventually merged with Allergan's generics spinoff and the Androxal program was shelved.

That CRL had two lasting consequences. First, enclomiphene remains without an FDA-approved indication to this day. Second, it pushed the entire supply chain into the compounding pharmacy sector.

How Enclomiphene Is Manufactured Today

Without an approved NDA or ANDA on file, enclomiphene citrate cannot be manufactured by traditional pharmaceutical companies for U.S. distribution. Instead, the drug reaches patients through two compounding pathways defined by the Drug Quality and Security Act (DQSA) of 2013 6.

503A pharmacies compound enclomiphene pursuant to individual patient prescriptions. These facilities operate under state pharmacy board oversight and are exempt from FDA current Good Manufacturing Practice (cGMP) requirements, though they must use bulk drug substances that meet USP or equivalent standards.

503B outsourcing facilities register with the FDA and can produce larger batches without patient-specific prescriptions. They are subject to FDA inspection, must follow cGMP, and must report adverse events. Several 503B facilities now list enclomiphene capsules (typically 12.5 mg and 25 mg strengths) in their catalogs.

The raw enclomiphene citrate API is synthesized by separating the trans-isomer from racemic clomiphene citrate through chiral resolution, most commonly via selective crystallization or chiral chromatography. A small number of API manufacturers, concentrated in Hyderabad (India) and Zhejiang province (China), supply the global compounding market. Because enclomiphene is not on the FDA's bulk drug substances list under section 503B by default, outsourcing facilities must demonstrate that their sourcing meets applicable quality standards, creating an additional compliance layer that limits the number of willing suppliers.

The Shortage Timeline: 2020 to Present

Enclomiphene supply disruptions have occurred in distinct waves, each driven by a different combination of factors.

2020 to 2021: COVID-era raw-material delays. Lockdowns in Gujarat and Maharashtra states disrupted intermediate chemical production for many APIs, including clomiphene-derived compounds. Export certifications from India's Central Drugs Standard Control Organisation (CDSCO) slowed. Compounding pharmacies reported lead times for enclomiphene API stretching from 4 weeks to 12 or more 7.

2022: Telehealth demand surge. Men's health telehealth platforms began offering enclomiphene as an alternative to testosterone replacement, driving prescription volume up sharply. One large 503B facility reported a 280% increase in enclomiphene capsule orders between Q1 2021 and Q4 2022. Raw API procurement did not scale at the same pace.

2023: FDA warning letters. The FDA issued warning letters to several compounding pharmacies for cGMP violations related to potency testing and sterility of non-sterile oral dosage forms. At least two 503B facilities temporarily halted enclomiphene production to remediate findings. Patients on stable enclomiphene regimens reported abrupt supply interruptions, sometimes lasting 6 to 10 weeks.

2024 to 2025: Regulatory uncertainty around bulk drug substance status. The FDA's continued review of which bulk drug substances can be used by 503B outsourcing facilities created uncertainty for enclomiphene. While enclomiphene citrate is not on the FDA's "difficult to compound" list, its absence from a finalized positive list has made some outsourcing facilities cautious about inventory commitments. Simultaneously, geopolitical tensions affecting chemical exports from China added another variable to API pricing and availability.

The cumulative effect: patients switching between compounding pharmacies, dose-strength mismatches, and periodic gaps in therapy that may compromise clinical outcomes.

Quality Control Challenges in Compounded Enclomiphene

Compounded medications face different quality-assurance standards than FDA-approved drugs, and enclomiphene is no exception. A 2019 FDA survey of compounded oral hormonal products found that approximately 29% of tested samples failed potency specifications, meaning they contained less than 90% or more than 110% of the labeled dose 8.

For enclomiphene specifically, the risk is compounded (no pun intended) by the need to verify isomeric purity. A capsule labeled "enclomiphene citrate 25 mg" must contain predominantly the trans-isomer, not a mixture contaminated with zuclomiphene. High-performance liquid chromatography (HPLC) with chiral columns can distinguish the isomers, but not all compounding pharmacies perform this assay routinely.

Dr. Mohit Khera, a urologist at Baylor College of Medicine and published researcher on enclomiphene, has noted: "The absence of an FDA-approved formulation means clinicians must rely on compounding pharmacies with varying quality-control rigor. Patients deserve to know whether their capsule contains what the label says it contains" 9.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy recommends that clinicians who prescribe compounded testosterone products (and by extension, compounded SERMs for hypogonadism) should verify that the pharmacy holds appropriate accreditation and performs batch-level potency and purity testing 10.

Why Enclomiphene Remains Unapproved

The FDA's decision to require cardiovascular outcomes data was not arbitrary. The TRAVERSE trial (N=5,204), published in the New England Journal of Medicine in 2023, was the first large randomized trial to assess cardiovascular safety of testosterone replacement therapy. It found that transdermal testosterone did not increase the incidence of major adverse cardiovascular events compared to placebo over a median follow-up of 33 months 11. That finding partially addressed the FDA's broader concern about androgen-modulating drugs, but no sponsor has stepped forward to fund a similar trial for enclomiphene specifically.

The economics are unfavorable. Enclomiphene's patent protection has expired. Any company that funds a cardiovascular outcomes trial and wins approval would face immediate generic competition, making it nearly impossible to recoup the estimated $150 to $300 million trial cost. This "generic cliff before launch" problem is well-documented in pharmaceutical development and explains why drugs with clear clinical utility can remain in regulatory limbo indefinitely.

A second pathway exists under the FDA's 505(b)(2) regulatory route, which allows a new drug application to rely in part on published literature and the agency's prior findings for clomiphene citrate. At least one company (unnamed, per SEC filings) explored this route in 2023 but has not announced an NDA submission.

Until an approved product reaches market, the compounding supply chain remains the only legal access point for U.S. patients, a reality that makes understanding that supply chain clinically relevant.

The Role of Telehealth in Shaping Demand

Men's health telehealth platforms have been the single largest driver of enclomiphene prescribing growth since 2020. These platforms typically position enclomiphene as a "fertility-friendly testosterone optimization" option, attractive to younger men (ages 25 to 40) who want hormonal support without suppressing spermatogenesis.

Prescription data from telehealth aggregators (not publicly audited) suggest that enclomiphene prescriptions grew from roughly 15,000 per quarter in early 2020 to over 50,000 per quarter by late 2024. That growth has outpaced the compounding sector's ability to source and verify API, contributing directly to the shortages described above.

The American Urological Association has not issued a formal position statement on enclomiphene, though its 2018 guideline on testosterone deficiency acknowledges clomiphene citrate (racemic) as an off-label option with Level C evidence 12. Enclomiphene's use extrapolates from that evidence base, supplemented by the smaller dedicated trials.

A second concern tied to telehealth prescribing is monitoring. The Endocrine Society recommends checking serum testosterone, LH, FSH, estradiol, and a complete blood count at baseline and at 3- to 6-month intervals for patients on any testosterone-modulating therapy 10. Whether telehealth platforms enforce this monitoring cadence consistently is an open question that directly affects patient safety.

What Clinicians and Patients Should Watch For

Three signals may indicate a supply disruption is imminent or ongoing. First, compounding pharmacies extending their standard fulfillment window beyond 7 to 10 business days. Second, pharmacies substituting a different capsule strength (e.g., sending 12.5 mg capsules when 25 mg was prescribed, with instructions to take two). Third, pharmacies offering racemic clomiphene citrate as a "therapeutic equivalent," which it is not, given the different isomer composition and pharmacokinetic profile.

Patients who experience a gap in enclomiphene therapy should understand that testosterone levels will typically decline toward pre-treatment baseline within 2 to 4 weeks of discontinuation, based on the drug's short half-life (approximately 10 hours for the trans-isomer). Unlike denosumab or GnRH agonists, there is no rebound phenomenon. But the return of hypogonadal symptoms (fatigue, decreased libido, mood changes) can be clinically significant and warrants prompt follow-up.

Dr. Larry Lipshultz, former president of the American Society for Reproductive Medicine, has stated: "Any interruption in SERM therapy for male hypogonadism should trigger a clinical reassessment, not just a pharmacy callback. The question is whether the patient still meets treatment criteria and whether the supply gap has changed their clinical trajectory" 13.

Looking Ahead: Regulatory and Supply Developments

The FDA's Pharmacy Compounding Advisory Committee continues to evaluate bulk drug substances for the 503B positive list. If enclomiphene citrate is formally added, it would give outsourcing facilities clearer authorization to compound it, potentially stabilizing supply. If it is excluded or restricted, the market would contract further to 503A pharmacies only, worsening access.

On the manufacturing side, at least two Indian API manufacturers have expanded enclomiphene production capacity since 2023, partly in response to demand from U.S. and European compounders. Whether that capacity translates to reliable supply depends on export-certification timelines and ongoing FDA scrutiny of foreign API facilities.

Patients currently prescribed enclomiphene citrate should confirm three things with their compounding pharmacy: the source and certificate of analysis for the API batch, the isomeric purity (trans-isomer content should exceed 99%), and the pharmacy's accreditation status (PCAB or equivalent for 503A; FDA registration for 503B).